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A B S T R A C T
The enzymatic complex 5α-reductase (5α-R) and 3α/3β-hydroxysteroid oxidoreductase (HSOR) is expressed in
the nervous system, where it transforms progesterone (PROG) and testosterone (T) into neuroactive metabolites.
These metabolites regulate myelination, brain maturation, neurotransmission, reproductive behavior and the
stress response. The expression of 5α-R and 3α-HSOR and the levels of PROG and T reduced metabolites show re-
gional and sex differences in the nervous system and are affected by changing physiological conditions as well as
by neurodegenerative and psychiatric disorders. A decrease in their nervous tissue levels may negatively impact
the course and outcome of some pathological events. However, in other pathological conditions their increased
levels may have a negative impact. Thus, the use of synthetic analogues of these steroids or 5α-R modulation
have been proposed as therapeutic approaches for several nervous system pathologies. However, further research
is needed to fully understand the consequences of these manipulations, in particular with 5α-R inhibitors.
1. Introduction
In addition to be a target for neuroactive steroids, the nervous sys-
tem has all the necessary molecular machinery for steroid synthesis
and metabolism. Thus, neural cells express the molecules involved in
the first and rate-limiting step of steroidogenesis, i.e., the transport of
cholesterol to the mitochondria. These molecules include steroidogenic
acute regulatory protein and translocator protein of 18 kDa (TSPO) (Gi-
atti et al., 2019d). Neural cells express also cytochrome P450 choles-
terol side-chain cleavage enzyme, which transforms cholesterol in preg-
nenolone within the mitochondria. Then, several steroidogenic enzymes
located in the endoplasmic reticulum of neurons and glial cells metabo-
lize pregnenolone in a variety of steroids, such as progesterone (PROG)
and testosterone (T) (Giatti et al., 2019d).
Among the steroidogenic proteins expressed by neural cells, the en-
zymatic complex formed by 5α-reductase (5α-R) and 3α- or 3β-hydrox-
ysteroid oxidoreductase (HSOR), plays a key functional role by the gen-
eration of reduced metabolites of PROG and T that have a potent activ-
ity on neurons and glial cells, acting on a variety of steroid and neuro
transmitter receptors and exerting a homeostatic regulation of neural
function and behavior (Celotti et al., 1992; Melcangi et al., 2008).
This enzymatic complex is very versatile, being able to reduce and
subsequently hydroxylate all steroids possessing the delta 4-3keto con-
figuration. For instance, PROG can be metabolized into dihydroproges-
terone (DHP) by the action of the enzyme 5α-R and subsequently into
3α, 5α-tetrahydroprogesterone (THP), also known as allopregnanolone,
or into 3β, 5α-tetrahydroprogesterone (isopregnanolone), by the action
of the enzyme 3α- or 3β-HSOR, respectively. Similarly, T can be con-
verted into dihydrotestosterone (DHT) and subsequently into 5α-an-
drostane-3α,17β-diol (3α-diol) or 5α-androstane-3β,17β-diol (3β-diol). In
the reactions producing 3α,5α-reduced metabolites, the enzymatic reac-
tion performed by 5α-R is the rate-limiting step (Dubrovsky, 2006).
Although we will center here our attention exclusively on PROG and
T metabolites, it is important to mention that these enzymes may also
convert corticosterone and deoxycorticosterone (DOC) into dihydrocor-
ticosterone and dihydrodeoxycorticosterone (DHDOC), respectively, and
this latter metabolite can be then further converted into 3α,5α-tetrahy-
drodeoxycorticosterone (THDOC).
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To exert they regulatory functions, the levels of PROG and T metabo-
lites generated by 5α-R and HSOR enzymes fluctuate in the nervous tis-
sue of developing and adult animals depending on the changing physi-
ological and endocrine conditions, with important differences between
males and females. In addition to these physiological changes, the levels
of PROG and T metabolites suffer also alterations in the nervous system
under psychiatric and neurodegenerative disorders. The significance of
these latter changes is still under debate and may either represent com-
pensatory adaptations to the pathological conditions or reflect a patho-
logical dysfunction in the activity of 5α-R and HSOR enzymes or, more
probably, a combination of both.
To discuss these questions, we present in the next sections a review
of our present knowledge on the expression and activity of 5α-R and
3α/3β-HSOR in the nervous tissue, focusing on the physiological func-
tions of the PROG and T reduced metabolites generated by these en-
zymes. We also examine the modifications in the levels of these metabo-
lites that occur in the central (CNS) and peripheral (PNS) nervous sys-
tem, discussing the possible consequences of these changes under physi-
ological and pathological conditions and their implications for the treat-
ment of psychiatric and neurodegenerative disorders.
2. 5α-Reductase characteristics and distribution in the nervous
system
To date, four genes have the SRD5A acronym in human genome (i.e.
SRD5A1, SRD5A2, SRD5A3 and SRD5A2L2), but only the first two en-
code for the enzyme 5α-R (i.e., called type 1 and type 2), able to gen-
erate the steroid metabolites mentioned above (Celotti et al., 1992;
Normington and Russell, 1992; Russell and Wilson, 1994; Stiles
and Russell, 2010). 5α-R type 3 is a polyprenol reductase with a cru-
cial role in N-linked protein glycosylation (Cantagrel et al., 2010) and
consequently seems not to be involved in steroid metabolism, with the
exception of a cancer prostatic model, where it is also associated with
DHT production and with maintenance of androgen signaling activation
(Uemura et al., 2008).
5α-R type 1 is expressed with high levels in regions of the CNS that
are particularly rich in white matter (i.e., midbrain, corpus callosum,
anterior commissure, optic chiasm, pons and spinal cord) (Celotti et
al., 1992; Melcangi et al., 1988a; Patte-Mensah et al., 2004). In
agreement with this, the enzyme is present in elevated concentrations
in purified myelin preparations obtained from the rat brain (Melcangi
et al., 1989; Melcangi et al., 1988a; Melcangi et al., 1988b) and
is expressed in oligodendrocytes, the myelin forming cells of the CNS,
and in neurons (Melcangi et al., 1990a; Melcangi et al., 1993; Mel-
cangi et al., 1994). In addition, 5α-R activity has been also detected
in Schwann cells, the myelinating cells of the PNS (Melcangi et al.,
1990b; Melcangi et al., 2001; Schaeffer et al., 2010; Yokoi et al.,
1998). In particular, the 5α-R activity in Schwann cells is at least four
times higher than in oligodendrocytes (Melcangi et al., 1998b).
5α-R type 1 is also present in microglia (Gottfried-Blackmore et
al., 2008) and astrocytes (Melcangi et al., 1993; Melcangi et al.,
1994). In particular, as reported in cell cultures, type 2 astrocytes,
which probably correspond to fibrous astrocytes in vivo, express the en-
zyme. In contrast, type 1 astrocytes, which probably correspond to pro-
toplasmatic astrocytes, do not express 5α-R type 1 (Melcangi et al.,
1993; Melcangi et al., 1994). Interestingly, 5α-R activity present in
type 1 astrocytes is stimulated by the simultaneous presence of neurons,
indicating a possible interaction of the two populations of cells in the
metabolism of neuroactive steroids (Melcangi et al., 1995).
5α-R type 1 mRNA has been also localized in cortical, hippocampal,
and olfactory bulb glutamatergic neurons and in some output neurons
of the amygdala and thalamus (Agis-Balboa et al., 2006). 5α-R type
2 is also widely expressed in most key regions of the adult rat brain,
ranging from the forebrain to the brain stem and cerebellum (Castelli
et al., 2013). However, its immunoreactivity is higher in the spinal
cord (i.e., dorsal and ventral horn of the gray matter) and particularly
in oligodendrocytes (Patte-Mensah et al., 2004). Finally, it should be
mentioned that not only differentiated CNS cells but also stem cells orig-
inating from the mouse striatum express 5α-R (Melcangi et al., 1996).
3. 3α/β-Hydroxysteroid oxidoreductase characteristics and
distribution in the nervous system
3α-HSOR is a member of the aldo-keto reductase superfamily which
includes aldehyde reductase, aldo-reductase and dihydrodiol dehydroge-
nase (Jez et al., 1997; Jez and Penning, 2001). Up to now, four hu-
man 3α-HSOR isozymes, but only one isoform in rats, have been cloned
(Penning et al., 2003).
The presence of 3α-HSOR and 3β-HSOR has been identified in the
CNS (Melcangi et al., 2014). For instance, 3α-HSOR mRNA levels have
been detected in the rat cerebral cortex and the cerebellum, with lower
expression in the latter structure (Giatti et al., 2019a). In addition,
the analysis of 3α-HSOR mRNA distribution in the mouse brain by in
situ hybridization has shown that this enzyme is co-localized with 5α-R
type 1 in neurons of the cerebral cortex, hippocampus, olfactory bulb,
amygdala and thalamus (Agis-Balboa et al., 2006). Furthermore, in
the spinal cord, 3α-HSOR immunoreactivity is largely distributed in both
white and gray matters, even if the highest density is present in sensory
regions of the dorsal horn (Patte-Mensah et al., 2004).
In addition to neurons, 3α-HSOR activity appears to be highly lo-
calized in glial cells, such as type 1 astrocytes in culture (Melcangi et
al., 1993; Melcangi et al., 1994) and oligodendrocytes (Gago et al.,
2001; Patte-Mensah et al., 2004), although, 3α-HSOR activity has
not been detected in myelin membranes of the CNS (Melcangi et al.,
1988a; Melcangi et al., 1988b). In oligodendrocytes 3α-HSOR activ-
ity is developmentally regulated. Indeed, as demonstrated by assessment
of progesterone metabolism, the formation of DHP in fully differentiated
oligodendrocytes is 5-fold higher than in oligodendrocyte pre-progeni-
tors and in oligodendrocyte progenitors, while that of THP is the oppo-
site (i.e., decrease with the differentiation of oligodendrocytes) (Gago
et al., 2001).
4. Physiological actions of 5α-reductase and 3α/β-Hydroxysteroid
oxidoreductase products of progesterone and testosterone in the
nervous system
The metabolites of PROG and T formed by the action of the enzy-
matic complex 5α-R and 3α- or 3β-HSOR have a profound physiological
impact in the nervous system, because they are also ligands for a vari-
ety of neuronal and glial receptors that are not directly modulated by
PROG and T (Fig. 1). The 5α-reduced metabolites of PROG and T (i.e.,
DHP and DHT) are agonists of progesterone (PR) and androgen receptor
(AR), respectively. The further 3α,5α-reduced metabolites interact with
different receptors. For instance, in the case of DHP metabolites, THP
is able to bind the GABA-A receptor, while isopregnanolone antagonizes
the effect of THP on this receptor (Belelli and Lambert, 2005; Gee et
al., 1988; Melcangi et al., 2008; Rupprecht, 2003). In the case of
DHT metabolites, 3α-diol and 3β-diol are agonists of GABA-A receptor
and ERβ, respectively (Handa et al., 2008; Melcangi et al., 2008).
4.1. Progesterone reduced metabolites
The physiological effects of progesterone metabolites have been sum-
marized in table 1. In particular, in the mammalian brain, and specifi-
cally in the female one, the main role of PROG and its reduced metabo-
lites is linked to the hypothalamic regulation of gonadotrophin re-
lease (Banks and Freeman, 1980; Barraclough et al., 1986) as
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Fig. 1. Biosynthesis of progesterone and testosterone metabolites and their mechanism of action. Single and bidirectional arrows indicate the irreversible and reversible reactions, re-
spectively. 3α-hydroxysteroid oxidoreductase: 3α-HSOR; 3β-hydroxysteroid oxidoreductase: 3β-HSOR; 5α-R: 5α-reductase; AR: androgen receptor; ARE: androgen responsive element; ER:
estrogen receptor; PR: progesterone receptor; PRE: progesterone responsive element. See text for further details.
well as to the control of reproduction and related behaviors (Laconi
and Cabrera, 2002; Levine et al., 2001; Mani and Portillo, 2010;
Mani et al., 1994; Mani and Oyola, 2012). The peak in the levels
of PROG observed during the estrous cycle, which is associated with an
increased PR expression in the hypothalamus (McGinnis et al., 1981a;
McGinnis et al., 1981b; Moguilewsky and Raynaud, 1979; Ro-
mano et al., 1989; Scott et al., 2002), is necessary for the lordo-
sis response, a behavioral mechanism facilitating copulation (Blaustein
and Feder, 1980; McGinnis et al., 1981a; McGinnis et al., 1981b;
Parsons et al., 1980). The inhibition of the brain synthesis of THP re-
duces this behavioral response (Frye et al., 2008b; Petralia et al.,
2005), indicating that THP is involved in the regulation of lordosis by
PROG. THP induces lordosis in an experimental model lacking PR (Frye
et al., 2006), suggesting that THP is acting in part through GABA-A re-
ceptor. Indeed, THP regulates lordosis and other motivated behaviors by
its action on GABA-A receptors located in the midbrain ventral tegmen-
tal area (Frye, 2011; Frye et al., 2008b). In addition, THP also acts
through PR to regulate lordosis, since the administration of mifepris-
tone, a PR antagonist, inhibits the induction of this behavioral response
by THP (Beyer et al., 1995; Gonzalez-Mariscal et al., 1989). This
action of THP through PR can be explained based on the ability of THP
to be retro-converted into DHP by 3α-HSOR (Belyaeva et al., 2007;
Chetyrkin et al., 2001; Penning, 2011).
Beside reproductive effects, PROG metabolites are also crucial for
mammalian brain maturation. Indeed, it is interesting to note that the
enzymes 5α-R type 1 and 2, are strongly expressed in the brain of fe-
tal and neonatal rodents (Martini et al., 1996). In agreement with
this, a critical role for THP in brain maturation has been demonstrated.
Indeed, the endogenous levels of this steroid fluctuate physiologically
during rodent fetal life and after birth (Grobin and Morrow, 2001).
These fluctuations may contribute to maintain the low level of arousal
activity, characteristic of fetal brain (Nicol et al., 1998). Moreover,
neonatal levels of THP promote the formation of neuronal circuitry and
support the survival of developing neurons (Griffin et al., 2004). This
neuroactive steroid is also involved in the structural formation of sev-
eral brain regions, such as the cerebral cortex, thalamus and hippocam
pus (Cooper et al., 1999; Grobin et al., 2006). Furthermore, PROG
and its metabolites are involved in oligodendrocyte differentiation
(Ghoumari et al., 2005) and myelin formation (Chan et al., 1998;
Chan et al., 2000; Ghoumari et al., 2003; Guennoun et al., 2001),
other crucial events for brain maturation.
Besides being necessary for brain maturation of the fetus, THP is also
important for the pregnant mother. Indeed, the higher levels of PROG
during pregnancy are related to a subsequent increase of THP levels in
the maternal peripheral circulation and in the maternal brain (Bicikova
et al., 2002; Concas et al., 1998). In particular, in rats, the rise
of this neuroactive steroid interferes with the hypothalamus-pituitarya-
drenal axis, reducing the response to stress exposure of the mother, in
particular during late pregnancy (Brunton et al., 2009; Brunton et
al., 2005; Ma et al., 2005; Neumann et al., 1998).
DHP and THP exert crucial functions in the adult brain, where the
enzymatic complex 5α-R and 3α-HSOR co-localizes in glutamatergic and
GABAergic neurons of the cerebral cortex, hippocampus, amygdala and
thalamus, suggesting that metabolites so formed are relevant for neu-
rotransmitter synthesis and the modulation of their activity in these
cells (Agis-Balboa et al., 2006). PROG metabolites are also active
in the cerebellum, where they regulate the neuronal cytoskeleton. In
particular, DHP or THP administration to ovariectomized animals de-
creases microtubule-associated protein Tau and glycogen synthase ki-
nase 3beta expression in the cerebellum but not in the hypothalamus
(Guerra-Araiza et al., 2007). In addition, protein content of glutamic
acid decarboxylase is increased by THP administration in the olfactory
bulb, suggesting that also this region is modulated by this PROG metabo-
lite (Guerra-Araiza et al., 2008).
The reduced metabolites of PROG are also involved in mood regula-
tion. In particular, THP acts in concert with glucocorticoids in the regu-
lation of the stress response. Thus, increased levels of THP and 3α,5α-de-
rivative of deoxycorticosterone (i.e., THDOC) have been observed in
plasma and cerebral cortex of adult male rats after swim stress (Purdy
et al., 1991). Interestingly, the expression of genes related to stress can
be modulated by these molecules in both sexes (Patchev and Almeida,
1996; Patchev et al., 1994).
3
UN
CO
RR
EC
TE
D
PR
OO
F
S. Giatti et al. Frontiers in Neuroendocrinology xxx (xxxx) xxx-xxx
Table 1
Actions of progesterone and testosterone metabolites in physiological conditions.
Steroid
Central Nervous
System
Peripheral
Nervous
System
DHP Reproductive
functions, lordosis
response
P0 expression
Glutamatergic
and GABAergic
neurotransmission
Krox-20 and
Sox-10
expression
Cytoskeleton
regulation
THP Lordosis response P0 and
PMP22
expression
Fetal brain
maturation
Krox-20
expression
Glutamatergic,
GABAergic and
dopaminergic
neurotransmission
Glutamic acid
decarboxylase
and
excitatory
amino acid
carrier 1
expression in
Schwann cells
HPA axis
regulation
Cytoskeleton
regulation
Norepinephrine
levels
DHT Neuronal and
glial cells
differentiation
P0 expression
Synaptic density
and transmission
3α-diol GABAergic
neurotransmission
P0 and
PMP22
expression
3β-diol HPA axis
regulation
THP also has a trophic effect on dopaminergic neurons (Wang,
2014) and is involved in the regulation of the dopaminergic system
(Cabrera et al., 2002; Khisti et al., 2002; Mosher et al., 2019).
In animals reared in social isolation, an experimental model in which
dopaminergic signaling is altered, show a reduction in the protein ex-
pression of 5α-R type 1 and 2 in the nucleus accumbens and in the
medial prefrontal cortex in comparison to animals subjected to social
rearing. The decreased expression of these enzymes was associated with
reduced levels of THP and THDOC in the brain but not in plasma
(Bortolato et al., 2011). Further evidence for the action of THP on
dopamine regulation was obtained using the foot shock stress, which in-
duces extracellular dopamine release from cortical dopaminergic neu-
rons. Reduction of THP levels by the administration of finasteride in
this model produces an amplification of dopamine release in the pre-
frontal cortex (Dazzi et al., 2002), while THP treatment completely
prevents the dopamine increase in the cerebral cortex and in the nu-
cleus accumbens (Motzo et al., 1996). THP also modulates dopamine
levels and dopamine metabolism during the estrous phase of the fe-
male ovarian cycle. Indeed, its administration decreases the levels of
dopamine and the dopamine metabolite 3,4-dihydroxyphenylacetic acid
in striatum (Laconi et al., 2007). Similarly, THP treatment decreases
dopamine output in the nucleus accumbens and prefrontal cortex in
freely moving rats (Motzo et al., 1996). On the other hand, in an
in vitro system, such as the PC12 pheochromocytoma cell line, THP
administration increases both dopamine and norepinephrine levels by
regulating catecholamine synthesis and their vesicle trafficking (Char-
alampopoulos et al., 2005).
PROG metabolites also exert a physiological role in the PNS. Indeed,
peripheral nerves as well as Schwann cells express PR and GABA-A re-
ceptors (Jung-Testas et al., 1996; Melcangi et al., 2011; Melcangi
et al., 1999). One of the actions of THP on Schwann cells is to en-
hance GABA synthesis through an increased expression of glutamic acid
decarboxylase (Magnaghi et al., 2010) and to promote glutamate up-
take through an increase in the excitatory amino acid carrier 1 (Perego
et al., 2011). In addition DHP and THP regulate the expression of
myelin proteins, such as glycoprotein zero (P0), in peripheral nerves
and Schwann cells. In cultured Schwann cells, mifepristone, a PR an-
tagonist, blocks the stimulatory effects of PROG or DHP on P0. Further-
more, treatment with mifepristone on postnatal (PN) day 1 decreases
P0 expression at PN day 20 in rats (Melcangi et al., 2003b). Taken
together, these data suggest that PROG metabolites enhance P0 expres-
sion by acting through PR in a classic genomic mechanism of action.
This is also implied by the fact that nuclear receptor coactivators are in-
volved in this regulation. This is the case of steroid receptor coactiva-
tor-1 (SRC-1), also known as NcoA-1, one of the first nuclear receptor
coactivators found to interact with hormone-bound steroid receptors, in-
cluding PR (Oñate et al., 1995). Thus, the over-expression of SRC-1
potentiates the DHP-induced increase in P0 expression in MCS80 immor-
talized Schwann cells. On the contrary, SRC-1 silencing eliminates this
increase in P0 expression (Cavarretta et al., 2004). In addition, pu-
tative PROG responsive elements have been identified on the P0 gene
(Magnaghi et al., 1999), further supporting the idea that P0 is regu-
lated by a classical steroid genomic mechanism. PROG metabolites also
affect myelination in Schwann cells by regulating the expression of spe-
cific transcription factors. For instance, Krox-20 expression is stimulated
by treatment with DHP or THP, while Sox-10 expression is enhanced by
DHP (Magnaghi et al., 2007).
In contrast to P0, the expression of peripheral myelin protein 22
(PMP22) is regulated by THP, but not by DHP, suggesting that this ef-
fect may be mediated by the GABA-A receptor (Melcangi et al., 2005;
Melcangi et al., 1999). Indeed, a GABA-A receptor antagonist (i.e.,
bicuculline) completely abolished the stimulatory effect exerted by THP
on PMP22 in Schwann cell cultures, while a GABA-A receptor agonist
(i.e., muscimol) had a stimulatory effect on PMP22 that was comparable
to that of THP (Magnaghi et al., 2001). A further support for the idea
that THP is acting on the GABA-A receptor to regulate PM22 expression
in Schwann cells is the finding that isopregnanolone, which does not di-
rectly interact with GABA-A receptor, does not alter PMP22 expression
either.
The effects of PROG metabolites on the expression of P0 and PMP22
are sexually dimorphic. Indeed, DHP treatment induces a stimulatory ef-
fect on P0 mRNA levels in primary Schwann cell cultures obtained from
male rats, but not in the cultures obtained from females (Magnaghi et
al., 2006). On the contrary, treatment with THP increases gene expres-
sion of P0 in female rat Schwann cells, but not in male cells. Similarly,
the expression of PMP22 is stimulated by THP in female, but not in male
Schwann cell cultures (Magnaghi et al., 2006).
4.2. Testosterone reduced metabolites
The physiological effects of testosterone metabolites have been sum-
marized in table 1. DHT is a selective and potent agonist for AR, show-
ing higher affinity for this receptor than its precursor T (Wilson and
French, 1976). The binding of DHT to AR triggers molecular mech-
anisms involved in the regulation of neuronal, glial and synaptic dif-
ferentiation and in the coordination of the appearance of typical male
features in specific brain regions (Cooke et al., 1998; Morris et al.,
2004). DHT regulates synaptic density and transmission in slice hip
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pocampal cultures from male rodents, but not from female animals.
Furthermore, the inhibition of DHT synthesis with finasteride, reduces
dendritic spine maturation and long-term potentiation (Brandt et al.,
2019).
In contrast to the high affinity of DHT for AR, its metabolites 3α-diol
and 3β-diol show a low affinity for this receptor. As mentioned above,
3α-diol binds to GABA-A receptor (Lambert et al., 1995; Majewska
et al., 1986; Paul and Purdy, 1992; Puia et al., 1990). Indeed,
this DHT metabolite has well known effects on behavior by the modi-
fication of GABA signaling (Frye, 2007; Rosellini et al., 2001). The
other DHT metabolite, 3β-diol, binds ERβ (Kuiper et al., 1997) but not
GABA-A receptor. ERβ is probably involved in the modulation exerted
by 3α-diol on the stress response mediated by HPA axis (Handa et al.,
2008). Thus, peripheral 3β-diol treatment is as effective as peripheral
DHT administration in reducing corticosterone and ACTH increases in
response to restraint stress (Lund et al., 2004a, b). These effects of
3β-diol are blocked by co-administration of the ER antagonist tamoxifen,
but not by the AR antagonist flutamide, suggesting that 3β-diol mediates
the effects of DHT on corticosterone and ACTH secretion by binding to
ERβ (Lund et al., 2006; Lund et al., 2004a, b).
T reduced metabolites also exert physiological effects in the PNS. For
instance, in adult male rats, orchidectomy decreases the expression of
P0 mRNA in the sciatic nerve, while subsequent treatment with DHT
or 3α-diol restores P0 mRNA to pre-castration levels (Magnaghi et al.,
2004; Magnaghi et al., 1999). Orchidectomy also decreases PMP22
mRNA levels in the rat sciatic nerve, but only 3α-diol treatment restores
PMP22 levels (Magnaghi et al., 2004). In agreement with these re-
sults, DHT and 3α-diol increase P0 and PMP22 mRNA levels, respec-
tively, in cultures of rat Schwann cells (Magnaghi et al., 1999; Mel-
cangi et al., 2000a).
5. Regulation of the levels of progesterone and testosterone
reduced metabolites in the nervous system under physiological
and pathological conditions
5.1. Physiological conditions
As revealed by liquid chromatography-tandem mass spectrometry
analyses (Fig. 2), the levels of reduced metabolites of PROG and T show
differences between the nervous system, plasma and cerebrospinal fluid
(CSF), between the CNS and PNS and between males and females on
diestrus day (Caruso et al., 2013b). In addition, the levels of DHP,
THP and isopregnanolone are higher in the brain of pseudopregnant fe-
males than in the brain of males (Meffre et al., 2007).
Sex differences in the levels of 5α-reduced PROG and T metabolites
may be due to a sex dimorphism of the steroidogenic enzymes synthe
Fig. 2. Levels of progesterone and testosterone reduced metabolites in physiological con-
ditions. Levels in different compartments of male and female (on diestrus day) rats. Higher
level in males or females with respect to the other sex. 3α-diol: 5α-androstane-3α,17β-diol;
CSF: cerebrospinal fluid; DHP: dihydroprogesterone; DHT: dihydrotestosterone; ISOPREG:
isopregnanolone (3β-5α-tetrahydroprogesterone); THP: 3α-5α-tetrahydroprogesterone.
sizing these molecules. For instance, in green anole lizards, there is a
higher gene expression of 5α-R type 2 in the brain of females than in
the male brain (Cohen and Wade, 2010). Sex differences in the brain
expression of 5α-R have been also observed in rats, where the mRNA
levels of this enzyme are significantly higher in the cerebellum of males.
In contrast, the mRNA levels of 3α-HSOR are significantly higher in
the cerebellum of proestrus females than in males. This sex dimorphism
does not occur in the cerebral cortex (Giatti et al., 2019a).
Another important consideration is that the levels of PROG and T re-
duced metabolites in the nervous system are influenced by its circulat-
ing levels. Indeed, gonadectomy affects the levels of these molecules in
the CNS and the PNS (Caruso et al., 2010b). Interestingly, the changes
induced by gonadectomy present specific features in different regions of
the nervous system, are different in the two sexes and depend on the
duration of gonadal hormone deprivation (Caruso et al., 2010b). Re-
cent results also indicate a sex specific effect of long-term gonadectomy
on the enzymes involved in the production of these metabolites. Thus,
a decrease of 3α-HSOR occurred in female, but not in male, cerebel-
lum (Giatti et al., 2019a). Altogether these results indicate that the
levels of the 5α-reduced metabolites of PROG and T present in the ner-
vous system under physiological conditions, even if influenced by the
steroid hormone environment, show specific patterns depending on sex
and brain region.
The levels of PROG and T reduced metabolites in the nervous sys-
tem are also affected by neurodegenerative and psychiatric disorders. In
some cases, these changes have been shown to be different in males and
females, in agreement with the fact that many neurodegenerative and
psychiatric disorders show a sex difference in term of incidence and/or
manifestations of the pathology. The main findings are discussed in the
following subsections.
5.2. Mental disorders
5.2.1. Alterations in steroidogenic enzymes and steroid levels
Altered THP plasma and/or CSF levels are a common finding in
stress-related disorders and psychiatric diseases (Bali and Jaggi, 2014;
Dong et al., 2001; Guidotti et al., 2001), suggesting that PROG me-
tabolism is altered under these pathological conditions. For instance,
anxiety-like behavior and depression are associated with decreased
plasma and/or CSF levels of THP (Frye et al., 2008a; Maguire, 2019;
Romeo et al., 1998; Rupprecht and Holsboer, 1999; Rupprecht
et al., 2010; Schule et al., 2014; Walf and Frye, 2012). Similar
changes have been observed in women affected by post-partum depres-
sion (Osborne et al., 2017) or post-partum anxiety (Osborne et al.,
2019). THP and 3α-diol plasma levels are also decreased in association
with increased depression and anxiety symptoms in anorexic and over-
weight/obese women (Dichtel et al., 2018). In agreement with these
changes in THP levels, the expression of 5α-R type 1 enzyme is down-
regulated in prefrontal cortex Brodmann’s area 9 of depressed patients
(Agis-Balboa et al., 2014).
Plasma levels of THP are decreased in human alcoholics during al-
cohol withdrawal and return to normal levels upon recovery (Romeo
et al., 1996). Modifications in THP levels and in the expression of
steroidogenic enzymes associated with alcohol consumption have been
also observed in animal models. Thus, ethanol treatment results in an in-
crease in the gene expression and protein levels of 5α-R type 1, 2 and 3
in the prefrontal cortex of adolescent male rats (Sanchez et al., 2014)
and THP levels are altered in the cerebral cortex and hippocampus after
ethanol withdrawal in mice (Jensen et al., 2017).
5.2.2. Functional implications
The decrease in 5α-R type 1 brain expression and in THP plasma
levels in depressed patients probably reflect an impaired neuroactive
steroid homeostasis that may contribute to the symptomatology or even
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to the pathogenesis of depression. Indeed, THP levels show a negative
correlation with the severity of depressive symptoms (Uzunova et al.,
1998). Furthermore, effective antidepressant treatments improve the re-
duced levels of THP in depressed patients (Griffin and Mellon, 1999;
Romeo et al., 1998; Strohle et al., 1999; Uzunova et al., 2006)
and fluoxetine (i.e., a selective serotonin reuptake inhibitor), increases
the brain levels of THP in rats (Fry et al., 2014), although this effect
was only detected in female animals.
Changes in the levels of THP in plasma, observed in human pa-
tients with post-traumatic stress disorders (PTSD), probably also reflect
an alteration in steroid metabolism contributing to the pathology. Thus,
THP is decreased in association with PTSD re-experiencing and depres-
sive symptoms in PTSD patients, as well as with enhanced contextual
fear memory and impaired fear extinction in PTSD experimental models
(Pinna, 2019).
Changes in PROG metabolism may also be implicated in patholog-
ical mechanisms in autism, since there is a significant association be-
tween single nucleotide polymorphisms rs523349 (Leu89Val) located in
SRD5A2 gene encoding 5α-R type 2 and autism (Zettergren et al.,
2013). In addition, knockout mice for 5α-R type 2 enzyme show reduced
dominance-related behaviors, as well as deficits of novelty-seeking and
risk-taking responses (Mosher et al., 2018). Polymorphic variations in
the enzymes 5α-R type 1 and 3α-HSOR have been also associated with
increased risk of alcohol dependence (Milivojevic et al., 2011).
Although THP levels are decreased in numerous affective and psychi-
atric disorders and THP treatment may alleviate depressive symptoms,
it is important to consider that in some cases the changes in THP levels
may represent a positive homeostatic mechanism to regulate GABA-A re-
ceptor activity and counterbalance the pathological alterations in synap-
tic activity caused by the disease. This is the case of premenstrual dys-
phoric disorder and Tourette syndrome, in which the treatment with iso-
pregnanolone, which inhibits the effects of THP on GABA-A receptors
(Belelli and Lambert, 2005; Gee et al., 1988; Melcangi et al.,
2008; Rupprecht, 2003), ameliorates the behavioral alterations (Bixo
et al., 2018; Mosher et al., 2017) (see also Section 6.1.).
5.2.3. Sex differences
The alterations in PROG metabolism in mood and anxiety disor-
ders may be different in males and females. For instance, environmental
stress in rats caused by artificial light, immobility in a small space and
excessive heat, results in an increased expression of 5α-R type 2 enzyme
in the brain of adult males, but in decreased expression in the brain of
females (Sanchez et al., 2009). Furthermore, THP levels are decreased
in the male, but not in the female brain in a mouse model of autism
spectrum disorder-like behavior induced by an inhibitor of the enzyme
5α-R type 1 and 2 (i.e., SKF105111) (Ebihara et al., 2017). In the
reeler mouse, another experimental model of autism, the levels of DHT
are decreased at postnatal day 5 in male, but not in female cerebellum,
a brain region that shows morphological alterations in autistic patients,
although other brain regions were not explored in this study (Biamonte
et al., 2009).
In human PTSD patients, decreased CSF levels of THP are associated
with impairment of 3α-HSOR in females (Rasmusson et al., 2006) and
of 5α-R in males (Rasmusson et al., 2019). In addition, THP levels are
decreased in the medial orbital frontal cortex of male patients, but not
in female patients with this pathology (Cruz et al., 2019). Changes in
THP brain levels associated with alcohol abuse are also different in men
and women. Thus, sex differences in THP immunoreactive levels, being
higher in men than in women, are detected in the substantia nigra pars
medialis in patients diagnosed with alcohol use disorder (Hasirci et al.,
2017).
5.3. Alzheimer’s disease
Changes in brain levels of PROG metabolites have been detected in
Alzheimer's disease (AD) mouse models, such as the 3xTg-AD mouse. In-
deed, the levels of DHP and its metabolite, isopregnanolone, are signifi-
cantly increased in the limbic region of 3xTg-AD male mouse in compar-
ison to what reported in wild type mice (Caruso et al., 2013a). Since
DHP exerts neuroprotective actions in experimental models of neurode-
generation (see Section 6.3.), the increase in its levels in the 3xTg-AD
mouse brain may represent an endogenous neuroprotective mechanism.
However, the significance of this finding for human pathology is un-
clear, because the levels of its metabolite THP are not significantly af-
fected by AD in the brain of human patients (Weill-Engerer et al.,
2002). Furthermore, although the existence of sex differences in AD is
well established (Mielke et al., 2014; Rahman et al., 2019), the in-
fluence of sex in the levels of PROG and T reduced metabolites in the
brain of AD animal models and patients remains to be determined. Nev-
ertheless, low plasma T levels are significantly associated with increased
risk of AD in elderly men (Lv et al., 2016), while higher free T lev-
els in women are associated with lower cerebral Aβ positivity (Lee et
al., 2017). This is also confirmed by assessment in postmortem human
brain tissue (Rosario et al., 2011).
5.4. Parkinsońs disease
Low DHP levels have been reported in the CSF of Parkinson's disease
(PD) patients (di Michele et al., 2003). In agreement with this find-
ing, the expression of the 5α-R type 1 enzyme is downregulated in the
substantia nigra, while that of 3α-HSOR type 3 is upregulated in the cau-
date nucleus (Luchetti et al., 2010). The levels of PROG and T reduced
metabolites are also altered in PD rodent models. Indeed, striatal lev-
els of DHP are decreased and those of isopregnanolone increased, by in-
jection with 6-hydroxydopamine to male rats (Melcangi et al., 2012),
while 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment increases
the brain levels of DHT in male mice (Bourque et al., 2016). This in-
crease in DHT levels in PD male mice may be an endogenous protec-
tive mechanism, because DHT is neuroprotective in PD animal models
(Bourque et al., 2009; Khasnavis et al., 2013). In contrast the de-
creased levels of DHP in PD models may impair the endogenous pro-
tective environment provided by this PROG metabolite. However, it is
still necessary to confirm these findings in humans. In addition, as men-
tioned for AD, there is still need of a comparative assessment of the lev-
els of PROG and T reduced metabolites in the brain of male and female
PD patients or experimental models, despite the higher incidence of the
disease in males (Benito-Leon et al., 2003; de Lau et al., 2004; Van
Den Eeden et al., 2003; Wooten et al., 2004) and the existence of
sex differences in the pathological alterations (Haaxma et al., 2007)
(Czlonkowska et al., 2006).
5.5. Multiple sclerosis
Altered levels of PROG and T reduced metabolites are detected in pa-
tients affected by multiple sclerosis (MS). For instance, increased levels
of isopregnanolone and 3α-diol, and decreased levels of DHP, DHT and
THP have been detected in the CSF of Relapsing-Remitting MS (RRMS)
male adult patients (Caruso et al., 2014). THP levels are also signifi-
cantly decreased in brain samples of male MS patients (Noorbakhsh et
al., 2011).
In agreement with these observations in humans, 5α-R expression in
the hippocampus and cerebral cortex is decreased in the mouse cupri-
zone demyelination model (Leicaj et al., 2018) and PROG and T re-
duced metabolites are affected in the CNS of experimental autoimmune
encephalomyelitis (EAE) rat MS model (Caruso et al., 2010a; Giatti
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et al., 2010). Interestingly, in this latter case, these changes depend on
the pathological phase considered and on the protocol used to induce
the pathology. For instance, the levels of DHP, DHT and 3α-diol are de-
creased in the spinal cord at the chronic phase of the disease after in-
duction with guinea pig spinal cord tissue in complete Freund's adjuvant
(Caruso et al., 2010a; Giatti et al., 2010), but not when the induc-
tion is made by syngeneic whole spinal cord homogenate suspended in
incomplete Freund's adjuvant (Giatti et al., 2013).
PROG and T reduced metabolites are protective in MS models (Noor-
bakhsh et al., 2014; Noorbakhsh et al., 2011) (Bebo et al., 1999;
Dalal et al., 1997; Giatti et al., 2015; Palaszynski et al., 2004).
Therefore, the decrease in their levels may contribute to increase the
manifestation of the pathological alterations and may contribute to sex
differences in the pathology. Indeed, different levels of PROG and T
reduced metabolites have been detected in male and female EAE ani-
mals, in agreement with the higher incidence of MS in females (Doo-
ley and Hogan, 2003; Gleicher and Barad, 2007; Jacobson et
al., 1997) and the existence of sex differences in MS symptomatology,
course of the disease, age of onset and pathological alterations (Golden
and Voskuhl, 2017). Interestingly, sex differences in PROG and T re-
duced metabolites in EAE animal models depend on the phase of pathol-
ogy considered. Indeed, THP levels are increased, while DHT and 3α-diol
levels are decreased, in the spinal cord of males, but not of females, at
the acute phase of the disease (i.e., 14 days post-immunization) (Giatti
et al., 2010). Furthermore, at the chronic phase (i.e., 40 days post-im-
munization), in addition to the decrease in DHT and 3α-diol levels ob-
served in the acute phase (Giatti et al., 2010), there is also a decrease
in the levels of DHP, also exclusively in males (Caruso et al., 2010a).
In the cerebellum, the acute and chronic phases of the disease are asso-
ciated with a significant decrease of isopregnanolone and 3α-diol levels
in males (Caruso et al., 2010a; Giatti et al., 2010). In contrast, in
the female cerebellum, THP levels are decreased at the acute phase of
the disease (Giatti et al., 2010), while at the chronic phase the levels
of isopregnanolone are increased and the levels of DHP and THP are de-
creased (Caruso et al., 2010a). In the male cerebral cortex, there is a
decrease in the levels of DHP, DHT and 3α-diol and an increase in the
levels of THP at the acute phase of the disease (Giatti et al., 2010).
Then, the levels of DHP and DHT remain decreased at the chronic phase
(Caruso et al., 2010a). However, none of these changes are detected
in the cerebral cortex of females (Caruso et al., 2010a; Giatti et al.,
2010).
Sex differences in PROG metabolites have been also detected in hu-
man RRMS patients. Thus, THP levels in the CSF are higher in male than
in female patients (Orefice et al., 2016). However, this difference is
observed in the active but not in the stable-phase, where the levels are
comparable in the two sexes. In addition, while male and female RRMS
patients with gadolinium-enhanced lesions showed comparable THP lev-
els, in RRMS patients without gadolinium-enhanced lesions the levels of
THP were lower in males than in females (Orefice et al., 2016).
5.6. Traumatic CNS injury and stroke
Brain levels of PROG metabolites (i.e., THP and isopregnanolone)
and of T, such as DHT, are affected in experimental model of traumatic
brain injury (TBI) (Lopez-Rodriguez et al., 2015; Lopez-Rodriguez
et al., 2016; Meffre et al., 2007). Spinal cord transection also affects
PROG metabolites, with an increase in DHP and THP levels (Labom-
barda et al., 2006). DHP levels are also increased six hours after mid-
dle cerebral artery occlusion in mice (Liu et al., 2012). These changes
may reflect an endogenous protective response, given the therapeutic ef-
ficacy of the treatment with DHP or THP in experimental stroke (Say-
eed et al., 2006) and TBI (Djebaili et al., 2005).
In agreement with the existence of sex differences in the incidence
and outcome of TBI and stroke (Bushnell et al., 2018; Mollayeva
et al., 2018), sex differences in PROG metabolites have been detected
in animal models of these CNS injuries. For instance, TBI results in in-
creased brain levels of isopregnanolone in pseudopregnant female rats
(Meffre et al., 2007) and in decreased brain levels of THP and isopreg-
nanolone in female mice (Lopez-Rodriguez et al., 2015). On the con-
trary, a decrease of DHT levels, associated with an increase in T levels,
was observed by 2 weeks after TBI in the brain of male mice, but not in
the female brain (Lopez-Rodriguez et al., 2016). Furthermore, cere-
bral levels of DHP are rapidly upregulated in male, but not in female
mice in an experimental model of middle cerebral artery occlusion (i.e.,
ischemic stroke model) (Zhu et al., 2017).
5.7. Diabetic encephalopathy
Diabetes alters brain function (i.e., diabetic encephalopathy) as well
as, as observed in animal models, the levels of PROG and T reduced
metabolites in the nervous system (Calabrese et al., 2014; Giatti et
al., 2018b; Pesaresi et al., 2010a; Pesaresi et al., 2010b; Romano
et al., 2017; Romano et al., 2018). The specific alterations in the
levels of these metabolites depend on the duration of pathology. For in-
stance, the levels of 3α-diol are decreased in the spinal cord of male rats
after long-, but not after short-term diabetes (Calabrese et al., 2014;
Pesaresi et al., 2010b).
Sex differences in the outcome of diabetic encephalopathy in hu-
mans and in animal models (Giatti et al., 2019b) have been also re-
ported and the observations obtained in streptozotocin (STZ) experimen-
tal model show that the nervous levels of PROG and T reduced metabo-
lites are modified in a sex-dimorphic way and with regional differences.
For instance, compared to control animals, the levels of THP are de-
creased in the spinal cord and those of DHT are decreased in the cerebral
cortex, cerebellum and spinal cord of diabetic males but not of diabetic
females (Pesaresi et al., 2010b). In contrast, the levels of DHP and iso-
pregnanolone are decreased in the cerebellum of both long-term diabetic
male and female rats (Pesaresi et al., 2010b). Although the conse-
quence of these changes in PROG and T reduced metabolites in the brain
of diabetic animals has not been fully explored yet, it is known that DHP
exerts protective effects on myelin in the spinal cord of diabetic rats (Pe-
saresi et al., 2010a) and that THP, DHP, DHT and 3α-diol exert protec-
tive effects in the peripheral nerves of diabetic animals (Afrazi et al.,
2014; Calabrese et al., 2014; Leonelli et al., 2007; Roglio et al.,
2007; Veiga et al., 2006). Therefore, the alterations in the levels of
these steroids in the brain of diabetic animals most probably will facil-
itate the progress of the pathological alterations associated to diabetic
encephalopathy.
5.8. Peripheral neuropathy
Animal models of peripheral neuropathy also show alterations in the
levels of PROG and T reduced metabolites (Caruso et al., 2008; Gi-
atti et al., 2018b; Pesaresi et al., 2011; Pesaresi et al., 2010b;
Roglio et al., 2008). For instance, alterations in PROG metabolites in
the sciatic nerve have been detected in a mouse model of peripheral
neuropathy, the sterol regulatory element binding protein-1C knockout
mice (Cermenati et al., 2015). In the sciatic nerve of these animals,
the levels of DHP and isopregnanolone are decreased at 2 months of age
and the levels of isopregnanolone and THP are increased at 10 months
of age, in comparison to those observed in wild type animals (Mitro et
al., 2017). In another model of peripheral neuropathy, the crush injury
of the sciatic nerve, a decrease in the levels of DHP and THP, associated
with a decrease in the expression of enzyme 5α-R, is observed in the dis-
tal portion of the injured nerve in male rats (Roglio et al., 2008).
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The decrease in the expression of 5α-R and in the levels of PROG and
T reduced metabolites has probably a negative impact for functional re-
covery from peripheral neuropathy, because several studies in different
animal models have shown that the treatment with these steroids im-
proves the structure and function of the damaged peripheral nerves (see
Section 6.4.). Thus, in this case, there is a clear potential application
of steroid therapy. However, as for other pathological conditions, it is
important to consider that sex specific changes in PROG and T metabo-
lites also occur in peripheral neuropathy. For instance, in the sciatic
nerve of male rats, but not in females, DHT levels are decreased and
those of THP are increased after one month of diabetes (Pesaresi et al.,
2018). Further sex differences are detected with longer duration of dia-
betes. Thus, by 3 months of diabetes a decrease in DHT and 3α-diol lev-
els are detected in the male rat sciatic nerve, while in females there is
a decrease in the levels of THP and isopregnanolone (Pesaresi et al.,
2010b). In another animal model of inherited peripheral neuropathy
(i.e., Charcot-Marie-Tooth disease type 1A), sexual differences in the lev-
els of some PROG and T reduced metabolites have also been identified.
Indeed, compared to control animals, the levels of isopregnanolone are
decreased in the peripheral nerves of female rats and those of 3α-diol
are decreased in the peripheral nerves of males (Caruso et al., 2008).
5.9. Neuropathic pain
Alterations in PROG metabolites are also associated with chronic
neuropathic pain. For instance, in animals with neuropathic pain in-
duced by peripheral nerve injury, the levels of THP are increased in
the spinal cord, together with an increased expression and activity of
3α-HSOR (Gonzalez et al., 2019). In this case, the increase in the
levels of THP and in the expression and activity of 3α-HSOR seem to
be an adaptive response to control pain (Patte-Mensah et al., 2010;
Patte-Mensah et al., 2014). In agreement with this interpretation, a
decreased expression of 5α-R type 1 and type 2 in the dorsal spinal cord
has been shown to be associated with the manifestation of allodynic
behaviors in animals with spinal cord injury (Coronel et al., 2016).
Furthermore, there is an increase in THP levels in the rat lateral thala-
mus (i.e., an important brain region for pain modulation) after spared
nerve injury (Zhang et al., 2016). Interestingly, in this experimental
model, THP levels are also increased in the hippocampus (Zhang et
al., 2017b), suggesting that PROG metabolites may also participate in
pain-associated emotions.
6. Therapeutic actions of the modulation of progesterone and
testosterone reduced metabolites in psychiatric and
neurodegenerative disorders
As mentioned above the levels of PROG and T metabolites are af-
fected in many neurodegenerative and psychiatric disorders. In agree-
ment, several therapeutic effects of the modulation of these metabolites
have been reported, as summarized in table 2 and here discussed in de-
tail.
6.1. Mental disorders
Anxiolytic and anti-stress actions of THP administration are well es-
tablished (Barbaccia et al., 2001; Zorumski et al., 2019). These ef-
fects are probably mediated by activation of GABA-A receptors, since
PROG administered to PR knockout mice is still able to exert anxiolytic
effects (Reddy et al., 2005). However, the anti-depressive effect of
THP, at least in the forced swimming model, seems to involve also the
stimulation of dopamine D2-like receptors (D'Aquila et al., 2010).
Sex specific features are an important component of the actions of
THP in mood and anxiety disorders. For instance, THP attenuates only
in females the HPA axis responses to interleukin-1β in adult prenatally
Table 2
Neuroprotective actions of progesterone and testosterone metabolites in pathological situ-
ations.
Steroid
Central Nervous
System
Peripheral
Nervous
System
DHP Stroke, oxygen-
glucose
deprivation,
traumatic brain
injury,
neurotoxicity
induced by kainic
acid or human
immunodeficiency
virus
Chemotherapy-
induced
peripheral
neuropathy
Diabetic spinal
cord cell
apoptosis
Diabetes-
induced
peripheral
neuropathy
High glucose level
toxicity on DRG
Nerve
transection
and crush
Myelin lipid
profile alteration
induced by
diabetes
Ageing-
induced
myelin
abnormalities
THP Anxiety,
depression and
stress
Diabetes-
induced
peripheral
neuropathy
HPA axis
activation
induced by IL1β
Ageing-
induced
myelin
abnormalities
Stroke, seizures,
traumatic brain
injury, multiple
sclerosis,
Alzheimer’s and
Parkinson’s
diseases, fragile X-
associated
tremor/ataxia
syndrome,
ischemic stroke
Chemotherapy-
induced
peripheral
neuropathy
Diabetic spinal
cord cell
apoptosis
Oxygen-glucose
deprivation,
neurotoxicity
induced by kainic
acid or human
immunodeficiency
virus
Reinstatement of
cocaine-seeking
behavior induced
by yohimbine
Isopregnanolone Premenstrual
dysphoric
disorder
Tourette
syndrome
DHT Multiple sclerosis,
Parkinson’s
diseases,
traumatic brain
injury
Diabetes-
induced
peripheral
neuropathy
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Table 2 (Continued)
Steroid
Central Nervous
System
Peripheral
Nervous
System
Apoptosis,
neurotoxicity
induced by kainic
acid, by serum
deprivation, or by
glutamate, acute
demyelination
Nerve injury-
induced
peripheral
neuropathy
3α-diol β-amyloid toxicity Diabetes-
induced
peripheral
neuropathy
Chemotherapy-
induced
peripheral
neuropathy
3β-diol HPA axis
activation
induced by IL1β
stressed rats, while 3β-diol normalized these responses in males (Brun-
ton et al., 2015). THP also blocks in females, but not in males, the
stress-induced reinstatement of cocaine-seeking behavior induced by
yohimbine (Anker and Carroll, 2010). Furthermore, although THP
has anxiolytic effects, women with premenstrual dysphoric disorder
show an altered sensitivity to THP over the menstrual cycle in compar-
ison to healthy controls, determined by recording the saccadic eye ve-
locity as a measure of GABA-A receptor activity (Timby et al., 2016).
Interestingly, THP effects are antagonized by the treatment in the pre-
menstrual phase with isopregnanolone, reducing negative mood symp-
toms in premenstrual dysphoric disorder (Bixo et al., 2018). In agree-
ment, isopregnanolone treatment has been also demonstrated to reduce
the number of tic-like behaviors induced by stress in D1CT-7 mice (i.e.,
an experimental model of Tourette syndrome) (Cadeddu et al., 2019).
Indeed, in the same experimental model, THP exacerbated the Tourette
syndrome-symptoms (Mosher et al., 2017).
6.2. Analgesic actions
Studies by Mensah-Nyagan and his collaborators have demonstrated
that 5α-R and 3α-HSOR are expressed in pain information processing
centers of the CNS, such as the dorsal root ganglia and the dorsal horn
of the spinal cord (Meyer et al., 2019; Patte-Mensah et al., 2010).
In addition, substance P, one of the main neuropeptides involving in
pain processing, regulates the synthesis of THP in the dorsal horn of
the spinal cord (Patte-Mensah et al., 2005). This suggests that en-
dogenous THP is involved in pain processing. Indeed, the silencing of
3α-HSOR and the consequent inhibition of the local synthesis of THP
in the dorsal root ganglia or in the spinal cord enhances neuropathic
pain induced by sciatic nerve injury (Patte-Mensah et al., 2010;
Patte-Mensah et al., 2014), while the pharmacological administration
of THP ameliorates diabetic-induced thermal hyperalgesia in the STZ
model (Afrazi et al., 2014). The analgesic actions of THP are, at least
in part, mediated by the potentiation of GABA-A receptor activity and
the inhibition of T-type Ca2+ channels (Pathirathna et al., 2005a;
Pathirathna et al., 2005b). In addition, not only THP, but also its
precursor DHP, suppress neuropathic symptoms (allodynia/hyperalge-
sia) evoked by antineoplastic drugs such as vincristine (Meyer et al.,
2010) and oxaliplatin (Meyer et al., 2011a).
T reduced metabolites also decrease neuropathic pain associated
with diabetes mellitus. Indeed, DHT and 3α-diol treatments are effec
tive on alterations of mechanical nociceptive threshold and tactile al-
lodynia induced by diabetes, respectively (Calabrese et al., 2014).
3α-diol is also able to exert beneficial effects on painful symptoms occur-
ring in paclitaxel-induced peripheral neuropathy (Meyer et al., 2013).
6.3. Neuroprotection in experimental models of neurodegeneration
Neuroprotective actions of PROG and T reduced metabolites have
been characterized in a variety of in vitro and in vivo models of neurode-
generation. DHP and THP are protective against kainic acid-induced ex-
citotoxicity in the hippocampus in vivo (Ciriza et al., 2006). In addi-
tion, THP treatment reduces seizures (Frye and Scalise, 2000), pre-
vents cell apoptosis in the spinal cord of STZ diabetic rats (Afrazi et
al., 2014) and protects against stroke (Sayeed et al., 2006), oxy-
gen-glucose deprivation (Ardeshiri et al., 2006), TBI (Djebaili et al.,
2005) and the neurotoxic effects exerted by human immunodeficiency
virus (Paris et al., 2016). THP is also able to reduce axonal injury
in EAE (Noorbakhsh et al., 2014; Noorbakhsh et al., 2011), and
it is protective in AD models, inducing neurogenesis/oligodendrogene-
sis and reducing β-amyloid levels (Irwin and Brinton, 2014; Irwin
et al., 2014) and bioenergetics deficits (Wang et al., 2019) as well
as in an experimental model of amyotrophic lateral sclerosis (i.e., Wob-
bler mouse) (Meyer et al., 2017). In PD experimental models, THP
is also able to improve cognitive dysfunction (Nezhadi et al., 2016)
and motor performance (Adeosun et al., 2012). In addition, a pi-
lot clinical study performed in patients affected by fragile X-associated
tremor/ataxia syndrome also show that THP treatment improves cog-
nitive function and some aspects of neurodegeneration (Napoli et al.,
2019; Wang et al., 2017).
Reduced metabolites of T also exert neuroprotective actions. For in-
stance, DHT is neuroprotective in experimental model of PD (Bourque
et al., 2009; Khasnavis et al., 2013), in EAE models (Bebo et al.,
1999; Dalal et al., 1997; Giatti et al., 2015; Palaszynski et al.,
2004) and in an experimental model of TBI (Barreto et al., 2007).
DHT is also able to protect hippocampal neurons from different dam-
ages, such as kainic acid injection (Ramsden et al., 2003), apoptosis
(Nguyen et al., 2010; Zhang et al., 2004) and serum deprivation
(Hammond et al., 2001). Moreover, it is also a protective agent for
motoneurons (Huppenbauer et al., 2005). However, DHT effects on
stroke are still unclear. Indeed, both protective and deleterious effects
have been reported (Quillinan et al., 2014).
The further metabolite of DHT, 3α-diol, exerts neuroprotective ef-
fects in SH-SY5Y neuronal cells and in primary cortical neurons, inhibit-
ing the phosphorylation of extracellular signal-regulated kinase induced
by amyloid β peptide 1-42. Interestingly, this effect is mediated by both
GABA-A receptor-dependent and independent mechanisms (Mendell et
al., 2018).
Altogether, these observations indicate that the PROG and T reduced
metabolites are neuroprotective agents. In this context, it is important to
highlight that most of the studies present in the literature and discussed
above have been conducted only in one sex. However, the protective ef-
fects exerted by the metabolites of PROG and T show sex specific fea-
tures. For instance, in cultured hippocampal neurons, DHT shows pro-
tective effects for apoptosis induced by glutamate in males, but not in fe-
males (Zup et al., 2014). THP exerts dose-dependent sex-specific neu-
roprotective actions in ischemic models. For instance, a low dose of this
DHP metabolite induces a higher neuroprotection from ischemic dam-
age in females than in males (Kelley et al., 2011). In epilepsy animal
model, THP shows greater antiseizure potency in females than in males
and this effect seems to be associated with a greater abundance of ex-
trasynaptic δ–subunit of GABA-A receptors in females (Reddy et al.,
2019).
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6.4. Neuroprotection in peripheral neuropathy
In the STZ experimental rat model of peripheral diabetic neuropa-
thy, THP treatment improves nerve conduction velocity, thermal thresh-
old and skin innervation density, while its precursor DHP, in addition
to these effects, also improves alterations in Na+,K+-ATPase activity
(Leonelli et al., 2007). Furthermore, DHP protects dorsal root ganglia
cultures exposed to high levels of glucose (Giatti et al., 2018b). Neuro-
protective effects of DHP have been also reported in other experimental
models of peripheral nerve damage, such as transection (Melcangi et
al., 2000a), crush (Roglio et al., 2008) and docetaxel-induced periph-
eral neurotoxicity (Roglio et al., 2009). Furthermore, DHP and THP
are also able to counteract the damage on peripheral nerves induced
by the aging process in rats (Azcoitia et al., 2003; Melcangi et al.,
2003a).
DHT and 3α-diol are also protective in the PNS. For instance, DHT
induces a faster regeneration and functional recovery of injured nerves
(Huppenbauer et al., 2005; Jones et al., 2001; Tanzer and Jones,
2004; Vita et al., 1983; Yu, 1982). In the STZ experimental diabetic
rat model, DHT stimulates the activity of Na+,K+-ATPase in the sci-
atic nerve and counteracts the impairment of nerve conduction velocity,
thermal sensitivity and skin innervation density (Roglio et al., 2007).
In this experimental model, also 3α-diol is able to reduce morphologi-
cal alterations in the sciatic nerve (Mitro et al., 2014) and to improve
nerve conduction velocity, thermal sensitivity and skin innervation den-
sity (Roglio et al., 2007).
6.5. Myelin protection
Myelin preservation is one of the protective actions of PROG metabo-
lites in both peripheral nerves and CNS. Thus, DHP and THP increase the
expression of myelin proteins, such as P0 and PMP22 (Melcangi et al.,
2003a; Melcangi et al., 1998a; Melcangi et al., 2000b) and exert
beneficial effects on the number and shape of myelinated fibers, reduc-
ing the frequency of myelin abnormalities (Azcoitia et al., 2003; Mel-
cangi et al., 2003a) in aged rats. THP also decreases demyelination
in EAE experimental model (Noorbakhsh et al., 2014; Noorbakhsh
et al., 2011). In addition, DHP counteracts the decreased expression of
P0 and PMP22 (Leonelli et al., 2007) and the increase in the number
of fibers with myelin infoldings in the sciatic nerve of STZ diabetic rats
(Veiga et al., 2006). This metabolite of PROG also increases the ex-
pression of myelin basic protein, in the spinal cord of STZ diabetic rats
(Pesaresi et al., 2010a).
Not only myelin proteins but also lipid components of the myelin
are targets for the protective effects of PROG metabolites. Indeed, by
promoting fatty acid desaturation, which is altered in STZ experimen-
tal model, DHP reduces myelin structural alterations in peripheral nerve
(Mitro et al., 2014) and restores to control levels the myelin lipid pro-
file in the cerebral cortex (Cermenati et al., 2017) of diabetic animals.
T reduced metabolites also exert protective actions on myelin. Thus,
in cerebellar organotypic cultures, DHT protects against acute demyeli-
nation (Hussain et al., 2013). In addition, in the STZ experimental
model, DHT stimulates the expression of P0 (Roglio et al., 2007) and
its metabolite 3α-diol reduces the accumulation of saturated fatty acids
in the myelin of sciatic nerve (Mitro et al., 2014).
6.6. Control of neuroinflammation
Control of neuroinflammation, a common aspect in neurodegener-
ative and psychiatric diseases (Glass et al., 2010; Meyer et al.,
2011b; Tansey, 2010; Tansey and Goldberg, 2010; Wee Yong,
2010; Wuwongse et al., 2010), is one of the crucial mechanisms of
neuroprotection by PROG metabolites (Giatti et al., 2012; Giatti et
al., 2019c). Indeed, THP reduces protein-protein interactions initiat-
ing the toll-like receptor 4-dependent signaling in immune cells and the
brain (Balan et al., 2019). Thus, THP decreases microglia reactivity
and lymphocyte infiltration in EAE experimental model (Noorbakhsh
et al., 2014; Noorbakhsh et al., 2011) and neuroinflammatory bur-
den in AD models (Irwin and Brinton, 2014; Irwin et al., 2014). In
ischemic stroke, THP downregulates the production of pro-inflammatory
cytokines, such as TNF-α and IL-6, protecting against BBB disruption and
reducing infarct size (Ishrat et al., 2010). In addition, THP decreases
the brain expression levels of IL-1β and TNF-α after TBI in rats (He et
al., 2004) and increases the expression of CD55, a potent inhibitor of
the complement convertases that are activators of the inflammatory cas-
cade (VanLandingham et al., 2007). T reduced metabolites also regu-
late neuroinflammation and gliosis. For instance, in the EAE model, DHT
reduces pro-inflammatory IFN-γ expression and gliosis in the spinal cord
(Giatti et al., 2015) and increases the expression of anti-inflammatory
IL-10 by autoantigen specific T lymphocytes (Dalal et al., 1997).
7. Limitations and alternatives for the use of progesterone and
testosterone reduced metabolites as therapeutic agents for the
nervous system
As reviewed in the previous section, PROG and T reduced metabo-
lites exert a variety of protective actions in the nervous system. There-
fore, it has been suggested that they may be used for neuroprotec-
tive pharmacological treatments. For instance, THP has been proposed
as potential candidate for the treatment of mood and anxiety disor-
ders (Wirth, 2011), neuropathic pain (Meyer et al., 2019), AD (Ir-
win et al., 2015), TBI (Reddy and Estes, 2016) or demyelinat-
ing diseases (Schumacher et al., 2014), among other nervous sys-
tem pathologies. The main disadvantages of the treatment with natural
steroid metabolites are represented by their rapid metabolism and their
low oral bioavailability. For these reasons, an extensive research has
been devoted to synthesize analogues of these molecules and particu-
larly of THP (Carter et al., 1997; Hogenkamp et al., 2014; Rey and
Coirini, 2015; Rey et al., 2015; Taleb et al., 2018).
Promising neuroprotective effects have been observed with some of
these analogues (Althaus et al., 2017; Karout et al., 2016; Reddy
and Estes, 2016; Rey et al., 2013; Zorumski et al., 2019). In
particular, there is an extensive literature on the neuroprotective ef-
fects of two synthetic analogues of THP, such as ganaxolone and brex-
anolone. Ganaxolone is neuroprotective in an experimental model of
Niemann-Pick Type-C, even if its effect is less robust than that exerted
by THP (Mellon et al., 2008). Ganaxolone also improves dysfunc-
tional emotional behavior in an animal model of PTSD (Pinna and Ras-
musson, 2014), ameliorates behavioral abnormalities in Angelman syn-
drome (Ciarlone et al., 2017), reduces preterm-associated neurode-
velopmental impairment following preterm birth (Shaw et al., 2019),
regulates GABA transport and neuroinflammation in MS (Paul et al.,
2014) and induces remyelination in focal demyelination of corpus cal-
losum (Mouihate and Kalakh, 2019). In addition, ganaxolone is ef-
fective for the treatment of ethanol withdrawal-induced seizures (Nip-
per et al., 2019) and exerts therapeutic effects in animal models of
epilepsy and related conditions (Chuang and Reddy, 2018; Saporito
et al., 2019; Zolkowska et al., 2018), being now under assessment
in clinical trials for the treatment of various seizure disorders (i.e., NC-
T03572933, NCT03865732 and NCT03350035).
Brexanolone, produced by Sage Therapeutics, has recently received
the approval of US Food and Drug Administration for the specific treat-
ment of post-partum depression (Meltzer-Brody et al., 2018; Zheng
et al., 2019; Zorumski et al., 2019). However, even if this molecule
may represent an important new treatment option, some concerns on
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its use have been raised (Cristea and Naudet, 2019; Morrison et al.,
2019).
An alternative to the use of synthetic steroids is to enhance the en-
dogenous synthesis of PROG and T reduced metabolites. One option for
this is the pharmacological activation of steroidogenesis with ligands of
TSPO, a molecule that forms part of the macromolecular complex in-
volved in the transfer of cholesterol into mitochondria (Papadopou-
los et al., 1997). Some TSPO ligands stimulate steroidogenesis, includ-
ing the synthesis of PROG and T reduced metabolites (Da Pozzo et
al., 2016; Papadopoulos, 2014; Papadopoulos et al., 2018), and
exert neuroprotective actions in animal models that depend on an in-
crease in the levels of these neuroactive steroids. This is the case of eti-
foxine (Daugherty et al., 2013) and XBD173 (Leva et al., 2017) in
EAE mice, midazolam (Miao et al., 2014) and YL-IPA08 in rat mod-
els of PTSD (Shang et al., 2019) and chronic stress-related depres-
sion (Zhang et al., 2017a), PK11195 in a rat ex vivo glaucoma model
(Ishikawa et al., 2016) and Ro5-4864 and AC-5216 in diabetic rats
(Mitro et al., 2012) (Giatti et al., 2009) (Qiu et al., 2016).
Activation of liver X receptors (LXRs) has been also shown to raise
the levels of PROG and T reduced metabolites in the nervous system.
For instance, the treatment with the LXR ligand GW3965 increases the
levels of DHP, THP, isopregnanolone and 3α-diol in the spinal cord and
the cerebral cortex and the levels of DHP and 3α-diol in the sciatic nerve
of diabetic rats (Cermenati et al., 2010) (Mitro et al., 2012). There-
fore, it is possible that PROG and T reduced metabolites mediate the
neuroprotective effects of LXRs reported in animal models of cerebral is-
chemia (Cheng et al., 2010), MS, AD and PD (Paterniti et al., 2017;
Xu et al., 2013). However, this has not been proved yet.
Interestingly, at least in the sciatic nerve, the protective effect of
LXR ligands is associated with an increase in the expression of 5α-R,
among other steroidogenic molecules (Cermenati et al., 2010). The
modulation of 5α-R activity has been proposed as a therapeutic treat-
ment for neuropsychiatric disorders in which excessive levels of PROG
or T reduced metabolites may have a negative impact, like for instance
Tourette syndrome and pathological gambling (Bortolato et al., 2008;
Fanni et al., 2019; Frau and Bortolato, 2019; Paba et al., 2011).
The 5α-R inhibitor dutasteride has been also shown to reduce alcohol
consumption in adult men (Covault et al., 2014). In addition, a clin-
ical study performed in women with premenstrual dysphoric disorder
showed that dutasteride reduces irritability, sadness, anxiety, food crav-
ings and bloating (Martinez et al., 2016).
Inhibitors of 5α-R have been reported to exert male-specific neu-
roprotective effects in experimental models of neurodegenerative dis-
eases in rodents, like dutasteride in an experimental model of PD (Litim
et al., 2015; Litim et al., 2017) or finasteride in ischemic brain
injury induced in aged rats (Tanaka et al., 2019). These male-spe-
cific effects of 5α-R inhibition are in agreement with the previously dis-
cussed sex differences in the neuroprotective actions of PROG and T
reduced metabolites. Indeed, the cellular and molecular consequences
of the inhibition of 5α-R are different in the male and female injured
brains (Golz et al., 2019), suggesting that the neuroprotective effects
depend on a different balance of PROG and T reduced metabolites in
each sex, which is also probably different for each pathological condi-
tion (Golz et al., 2019). However, we are still far from a fully un-
derstanding of this protective steroid balance and we have an incom-
plete knowledge on all the possible neurological and psychiatric con-
sequences of 5α-R inhibition. Indeed, serious endocrine and neuropsy-
chiatric side effects (i.e., erectile and ejaculatory dysfunctions, loss of
libido, depression, anxiety, suicidal thoughts and sleep problems) have
been reported in a subset of male patients treated with 5α-R inhibitors
for androgenetic alopecia. Importantly, these effects may persist despite
treatment suspension (Diviccaro et al., 2020; Giatti et al., 2018a;
Irwig, 2012a, b; Traish et al., 2015), a situation that has received the
name of post-finasteride syndrome. Interestingly, alterations in the
methylation pattern of the gene encoding for 5α-R type 2 and in the lev-
els of the reduced metabolites of PROG and T have been detected in the
CSF of patients with this syndrome (Melcangi et al., 2019; Melcangi
et al., 2017). These alterations further emphasize the need for an ade-
quate understanding of the role of 5α-R for neural function.
8. Conclusions
The studies reviewed here indicate that the generation of PROG and
T reduced metabolites in the nervous system has regional and cellular
specificity, which is the result of the cell-specific expression of the en-
zymes 5α-R and 3α- and 3β-HSOR. In addition, the action of the enzy-
matic products of 5α-R and 3α/β-HSOR also shows cellular and regional
specificity, since it depends on receptors that are not homogeneously
distributed in the nervous tissue, such as AR, PR and ERβ, or that have
a different regional and subcellular subunit composition that determines
steroid actions, as is the case for the GABA-A receptor (Belelli and
Lambert, 2005). The significance of this regional specificity of action is
still unclear, but suggests that PROG and T reduced metabolites may act
as neuromodulators, modifying neurotransmission or intracellular sig-
naling in a specific cell to cell communication manner. Indeed, the neu-
romodulatory action of these neuroactive steroids has been ascertained
in some cases, such as in the control of pain (Meyer et al., 2019). How-
ever, this possible neuromodulatory role remains to be ascertained for
other functions of PROG and T reduced metabolites.
An important aspect that has been reviewed here is the existence of
sex differences in the physiological effects exerted in the nervous system
by PROG and T reduced metabolites. As we have seen, this is also asso-
ciated with dissimilar levels of these steroids in males and females. The
function of these differences is unclear, except for those that may be in-
volved during development in the generation of a sex dimorphic brain
differentiation. In the adult brain, dissimilar levels and actions of PROG
and T reduced metabolites in males and females may be involved in the
generation of sex dimorphic behaviors, but they may also represent a
compensation for the sexually differentiated actions of sex steroids. This
latter possibility has not been received enough attention yet.
Similar considerations may apply for the observed differences in the
levels and actions of PROG and T reduced metabolites in neurodegener-
ative and psychiatric disorders in males and females. Here, in addition,
it is unclear whether these differences are a cause or a consequence of
the specific manifestation of the pathological alterations in each sex, be-
cause, in general, the available observations on steroid changes in ner-
vous tissue under pathological conditions are mere correlations. How-
ever, it is clear that some PROG and T reduced metabolites exert neu-
roprotective actions, suggesting that a decrease in their levels may en-
hance the pathological alterations, while their increase under patholog-
ical conditions may represent an endogenous neuroprotective mecha-
nism. In contrast, as we have discussed before, excessive levels of PROG
or T reduced metabolites may have a negative impact in other patho-
logical situations, such as in Tourette syndrome, pathological gambling
and premenstrual dysphoric disorder. Of course, this information sup-
ports possible therapeutic interventions using synthetic steroid analogs
to enhance steroid signaling or using inhibitors for 5α-R, the rate lim-
iting step in the generation of PROG and T reduced metabolites, to de-
crease steroid signaling. While proofs of concept for such treatments
are well established in animal models and good results have been also
obtained in some human conditions, in particular with the use of syn-
thetic steroids, further research is still necessary to determine the effi-
cacy and safety of such treatments in humans, in particular considering
their possible long-term effects and their different consequences in men
and women.
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